Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential

Thrombosis and Haemostasis

Volumn 93, Issue 2, 2005, Pages 306-310

  Zotz, Rainer B ^a   Gerhardt, Andrea ^a   Kluft, Cornelis ^b   Scharf, Rüdiger E ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b TNO   (Netherlands)

Author keywords

APC sensitivity ratio (nAPCsr); Endogenous thrombin potential (ETP); Pregnancy; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); ORAL CONTRACEPTIVE AGENT;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEIN C; RISK FACTORS; THROMBIN; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 13844272125     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-06-0372     Document Type: Article

References (19)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by a poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993; 94: 1004-8.
2. Bertina RM, Koeleman PC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-6.
3. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-3.
4. Hallak M, Senderowicz J, Cassel A, et al. Activated protein R resistence (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176: 889-93.
5. Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-8.
6. Rosing J, Hemker HC, Tans G: Molecular biology and pathophysiology of APC resistance. Sem Thromb Hemost 1998; 24: 329-35.
7. Kluft C, de Maat MPM, Heinemann LAJ, et al. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet 1999; 354: 832-3.
8. Curvers J, Thomassen MC, Nicolaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94.
9. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet 1999; 354: 2036-40.
10. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
11. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood 1996; 88: 3698-703.
12. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease in methylenetetrahydrofolate-reductase. Nat Genet 1995; 10: 111-3.
13. Kluft C, Meijer P, Gram J, et al. Acquired activated protein-C resistance. Lancet 1999; 353: 1882.
14. De Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
15. Tans G, Rosendaal FR, Curvers J, et al. APC resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis: a blinded evaluation. Thromb Haemost 1999; 82(suppl) abstract 640: 202-3.
16. Grand'Maison A, Douketis J, Bates SM, et al. Endogenous thrombin potential and the risk of venous thromboembolism. Blood 2000; 96: 95b.
17. Kluft C. Renewed interest in haemostasis changes induced by oral contraceptives. Thomb Haemost 2000; 84(1): 1-3.
18. Heinemann LAJ, Kluft C, Spannagl M, et al. The association between extrinsic activated protein C resistance and venous thromboembolism in women. Contraception 2002; 66: 297-304.
19. Hoibraaten E, Mowinckel MC, de Ronde H, et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001; 115: 415-20.